The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells by Morell, C. et al.
                                                              
University of Dundee
The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP
prostate cancer cells
Morell, C.; Bort, A.; Vara , D.; Ramos-Torres, A.; Rodríguez-Henche, N.; Díaz-Laviada, I.
Published in:
Prostate Cancer and Prostatic Diseases
DOI:
10.1038/pcan.2016.19
Publication date:
2016
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Morell, C., Bort, A., Vara , D., Ramos-Torres, A., Rodríguez-Henche, N., & Díaz-Laviada, I. (2016). The
cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells. Prostate
Cancer and Prostatic Diseases, 19, 248-258. DOI: 10.1038/pcan.2016.19
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
OPEN
ORIGINAL ARTICLE
The cannabinoid WIN 55,212-2 prevents neuroendocrine
differentiation of LNCaP prostate cancer cells
C Morell1, A Bort1, D Vara2, A Ramos-Torres1, N Rodríguez-Henche1 and I Díaz-Laviada1
BACKGROUND: Neuroendocrine (NE) differentiation represents a common feature of prostate cancer and is associated with
accelerated disease progression and poor clinical outcome. Nowadays, there is no treatment for this aggressive form of prostate
cancer. The aim of this study was to determine the inﬂuence of the cannabinoid WIN 55,212-2 (WIN, a non-selective cannabinoid
CB1 and CB2 receptor agonist) on the NE differentiation of prostate cancer cells.
METHODS: NE differentiation of prostate cancer LNCaP cells was induced by serum deprivation or by incubation with interleukin-6,
for 6 days. Levels of NE markers and signaling proteins were determined by western blotting. Levels of cannabinoid receptors were
determined by quantitative PCR. The involvement of signaling cascades was investigated by pharmacological inhibition and small
interfering RNA.
RESULTS: The differentiated LNCaP cells exhibited neurite outgrowth, and increased the expression of the typical NE markers
neuron-speciﬁc enolase and βIII tubulin (βIII Tub). Treatment with 3 μM WIN inhibited NK differentiation of LNCaP cells. The
cannabinoid WIN downregulated the PI3K/Akt/mTOR signaling pathway, resulting in NE differentiation inhibition. In addition, an
activation of AMP-activated protein kinase (AMPK) was observed in WIN-treated cells, which correlated with a decrease in the NE
markers expression. Our results also show that during NE differentiation the expression of cannabinoid receptors CB1 and CB2
dramatically decreases.
CONCLUSIONS: Taken together, we demonstrate that PI3K/Akt/AMPK might be an important axis modulating NE differentiation of
prostate cancer that is blocked by the cannabinoid WIN, pointing to a therapeutic potential of cannabinoids against NE prostate
cancer.
Prostate Cancer and Prostatic Diseases advance online publication, 21 June 2016; doi:10.1038/pcan.2016.19
INTRODUCTION
Prostate cancer is one the most common prevalent cancer among
men worldwide and the second cause of cancer-induced deaths in
western countries.1
A distinctive feature of prostate cancer is the occasional
appearance within the prostate tumor mass of a large number
of single or clustered neuroendocrine (NE) cells, a situation called
NE prostate cancer. NE cells secrete neuropeptides that induce
mitogenic effects on prostate cancer cells.2 The NE cells are
deﬁned immunohistochemically by the presence of cytoplasmic
markers, such as, chromogranin A, neuron-speciﬁc tubulin 3 (βIII
tubulin) and neuron-speciﬁc enolase (NSE).3 NE prostate cancers
become rapidly growing and highly aggressive,4 as NE cells might
contribute to the regrowth of prostate cancer cells that have
adapted to the hormone-deprived environment or the absence of
androgen receptor stimulation.5 In fact, NE prostate cancer usually
occurs as a recurrent tumor in men who have received hormonal
therapy for prostatic adenocarcinoma, and its presence correlates
with tumor progression and poor prognosis.6,7
The origin of NE cells in prostate cancer is under discussion. It is
thought that NE-like cells come from a ‘epithelial-to-neuroendo-
crine’ transition process of prostate cancer cells, known as
NE differentiation, as they differ in some aspects from NE cells
present in the normal prostate. NE differentiation is a
well-recognized phenotypic change by which prostate cancer
cells transdifferentiate into NE-like cells. Nevertheless, the
mechanism underlying NE differentiation remains still unclear,
and the management of patients with NE prostate cancer
is a challenge for oncologists. Therefore, novel therapies are
needed for this clinically signiﬁcant and deﬁant variant of prostate
cancer.8
Over the last decade, several research groups including ours
have proposed that cannabinoid receptor agonists exert a direct
antitumor activity in a variety of aggressive cancers. In prostate
cancer cells, natural and synthetic cannabinoids have been shown
to inhibit cell growth in culture and in experimental animal
models.9–11 Numerous investigations demonstrate the ability
of cannabinoids to inhibit prostate cancer cells’ viability/prolifera-
tion, as well as invasion and metastasis.12,13 The expression of
cannabinoid receptors in prostate cancer cells is higher than
that in corresponding non-malignant tissues,14 and also the
enzymes responsible for cannabinoid degradation, suggesting
that the endocannabinoid system has a role in prostate
growth.10,15 Two cannabinoid receptors, CB1 and CB2, have been
identiﬁed to date and belong to a Gi/o family of receptors
presenting seven transmembrane domains.16,17 The mechanisms
by which activation of cannabinoid receptors affect prostate
cancer cell survival are quite diverse and a matter of current
research. Moreover, receptor-independent effects also mediate
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many of the antiproliferative actions of cannabinoid ligands on
prostate tumor cells.18
Herein, we explored the potential role of the synthetic
cannabinoid WIN 55,212-2 (WIN) on serum deprivation-induced
NE differentiation of prostate LNCaP cells.
MATERIALS AND METHODS
Materials
The cannabinoid WIN 55-212,2 (WIN) was purchased at Sigma (St Louis,
MO, USA). The CB1 antagonist SR-141716 and the CB2 antagonist
SR-144528 were kindly provided from Sanoﬁ-Synthelabo (Montpellier,
France). The anti-p-S6, p-p70S6K, p-AKT-ser473, p-mTOR, p-AMPKα1-
thr172, p-ACC-ser79 and the antibodies against the corresponding total
forms were obtained from Cell Signaling Technology (Danvers, MA, USA).
The anti-βIII Tub polyclonal antibody was obtained from Covance
(Princeton, NJ, USA). The anti-NSE monoclonal antibody was obtained
from Dako (Glostrup, Denmark). Recombinant human interleukin-6 (IL-6)
was purchased at Prepotech (New York, NY, USA) All the other chemicals
were obtained from Sigma.
Cell culture
Human prostate epithelial LNCaP (ATCC CRL-1740) and PC-3 (ATCC
CRL-1435) cells were purchased frozen from American Type Culture
Collection (Rockville, MD, USA). All the experiments were performed with
cells at passages 3–15. Cells were routinely grown in RPMI 1640 medium
supplemented with 100 IU ml− 1 penicillin G sodium, 100 μg ml− 1
streptomycin sulfate, 0.25 μg ml− 1 amphotericin B (Invitrogen, Paisley,
UK) and 10% fetal calf serum. For androgen deprivation-induced NE
differentiation, the medium was replaced for serum-free RPMI 1640 and
then incubated for 6 days. For NE differentiation induced by long
treatment with IL-6, 20 ng ml− 1 of human recombinant IL-6 was added to
the medium and the cells were incubated for 6 days.
Immunoﬂuorescence staining
Cells were plated on glass coverslips and immunoﬂuorescence was
performed as previously described.19
Proliferation assay
Cells were seeded in a 12-well plate at 5000 cells per well, maintained for
24 h and then treated with increasing concentrations of WIN with or
without 10% fetal bovine serum for 6 days, according to the experiment.
MTT cell viability assay was performed as previously described.20
Immunoblotting assay
LNCaP cells were washed with phosphate-buffered saline and lysed in a
lysis buffer (50 mM Tris pH 7.4, 0.8 M NaCl, 5 mM MgCl2, 0.1% Triton X-100)
containing Protease Inhibitor and Phosphatase inhibitor Cocktails (Roche,
Basel, Switzerland), and cleared by microcentrifugation. Western blotting
was performed as previously described.19
Real-time quantitative PCR
Complementary DNA was obtained from cells using Transcriptor (Roche
Applied Science, Indianapolis, IN, USA). Real-time quantitative PCR assays
were performed using the FastStart Universal Probe Master mix with Rox
(Roche Applied Science), and probes were obtained from the Universal
ProbeLibrary Set (Roche Applied Science); CB1 sense primer 5′-CATTA
AGACGGTGTTTGCATTCT-3′; CB1 antisense primer 5′-CGTGTCGCAGGTCC
TTACTC-3′; CB2 sense primer 5′-GACACGGACCCCTTTTTGCT-3′; CB2
antisense primer 5′-CCTCGTGGCCCTACCTATCC-3′ or from Ambion
(Life Technologies, Carlsbad, CA, USA). Ampliﬁcations were run in a 7900
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Figure 1. The synthetic cannabinoid WIN 55,212-2 (WIN) inhibits NE differentiation of LNCaP cells. (a) NE differentiation cells was induced by
serum deprivation of LNCaP for 6 days. Cell morphology of control LNCaP cells (control, C) and serum-deprived cells (NE cells) was monitored
by phase-contrast microscopy (upper panel) and immunoﬂuorescence of class III β Tubulin (βIII Tub, red) counterstained with DAPI (blue)
(lower panel). (b) Expression of the NE markers neuron-speciﬁc enolase (NSE) and βIII Tub in control and NE cells. GADPH was probed as a
loading control. (c) LNCaP control cells (C) and NE cells were incubated with increasing concentrations of WIN for 48 h and cell viability was
monitored by MTT. (d) LNCaP control cells and NE cells were treated with vehicle (Vhc), 3 μM of WIN (WIN) or 1 μM of the CB1inverse agonist
SR1 and 1 μM of the CB2 inverse agonist SR2 (SR1/SR2) for 6 days. Levels of the NSE and βIII Tub were determined by western blot. GADPH was
probed as a loading control. The image is representative of other four experiments. Densitiometric analysis of the western blot bands is shown
on the right. The data shown are the means± s.d. of four different experiments (*Po0.05 and **Po0.01 versus control cells, #Po0.05 and
##Po0.01 versus NE, compared by the Student’s t-test). NE, neuroendocrine.
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HT-Fast Real-time PCR System (Applied Biosystems, Foster City, CA, USA).
Each value was adjusted by using 18S RNA levels as a reference.
Animal study
Eight male athymic nude-Foxn1 (nu/nu) mice aged 4 weeks were
purchased from Envigo RMS (Barcelona, Spain), and housed under speciﬁc
pathogen-free conditions in a 12-hour light–dark cycle at 21–23 °C and
40–60% humidity with access to food pellets and tap water ad libitum. All
animal studies were conducted in accordance with the Spanish institu-
tional regulation (Decree 53/2013) for the housing, care and use of
experimental animals with the approval of the Institutional Animal Care
and Use Committee of Alcala University and by Comunidad de Madrid
(PROEX 241/15). This study met the European Community directives
regulating animal research. Recommendations made by the United
Kingdom Coordinating Committee on Cancer Research (UKCCCR) have
been kept carefully.
After 1-week adaptation period, mice were injected subcutaneously in
the right ﬂank with 5 × 106 PC-3 cells in 0.1 ml of phosphate-buffered
saline+0.5% BSA to induce prostate cell tumors. Tumor sizes were
measured everyday and calculated using the formula V (mm3) = 1/2
(length×width2). When tumors reached a volume of 100 mm3 (~2 weeks
after transplantation), the mice were randomly divided into two groups
(n=4) and daily treated subcutaneously. with vehicle, or 0.5 mg kg− 1 WIN
55,212-2 for 15 days. At the end of the study, the mice were killed by
placing them in a CO2 gas-ﬁlled chamber, and the excised tumors were
recovered and homogenized in lysis buffer for protein quantiﬁcation and
western blotting.
Statistical analysis
All experiments were executed at least three times and performed in
triplicate. The statistical signiﬁcance of differences between the means was
evaluated using the unpaired Student’s t-test. The level of signiﬁcance was
set at P⩽ 0.05. Calculations were performed using Instat (Graphpad
Software, San Diego, CA, USA).
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Figure 2. Inhibition of NE differentiation by WIN 55,212-2 (WIN) in IL-6 long treated LNCaP cells and in PC-3 cells. (a) NE differentiation of
LNCaP cells was induced by incubation with IL-6 (20 ng ml1) -supplemented medium for 6 days. Cells were treated with vehicle (Vhc), 3 μM of
WIN (WIN) or 1 μM of the CB1inverse agonist SR1 and 1 μM of the CB2 inverse agonist SR2 (SR1/SR2) for 6 days. Levels of the NE markers
neuron-speciﬁc enolase (NSE) and βIII tubulin (βIII Tub) were determined by western blot. (b) NE markers NSE and βIII Tub in PC-3 cells treated
as above. The image is representative of other three experiments. GADPH was probed as a loading control. Densitiometric analysis of the
western blot bands is shown on the right. The data shown are the means± s.d. of three different experiments (*Po0.05 versus control cells,
compared by the Student’s t-test). (c) Effect of WIN on PC-3 growth and βIII Tub expression in vivo. PC-3 xenografts were generated by
subcutaneously. injection in athymic mice (n= 8). When tumors reached 100 mm3 volume, mice were randomly divided into two groups and
treated with 0.5 mg kg1 WIN or vehicle. Graph represents tumor growth from the ﬁrst day of treatment and results are expressed as the
mean± s.e.m. of the size of the tumor. A representative image of the tumor at the end of the treatment is shown on the right. Down, levels of
βIII Tub in the dissected tumors. IL, interleukin; NE, neuroendocrine.
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RESULTS
The synthetic cannabinoid receptor ligand WIN prevents NE
differentiation induced by serum-deprivation of prostate
LNCaP cells
Different cell models have been used for understanding the
molecular mechanisms of NE differentiation. The most widely used
is the experimental manipulation of the androgen-sensitive
prostate cancer cell line LNCaP to induce a transition into a NE
phenotype. This phenotypic switch has been seen especially when
cells are grown in hormone-depleted medium.21 In order to mimic
the situation of androgen removal, prostate LNCaP cells were
incubated in the absence of serum for 6 days. Cells grown in the
absence of serum stop division and stay quiescent (Supple-
mentary Figure 1). As seen in Figure 1a, serum deprivation of
LNCaP cells for 6 days induced a NE-like phenotype corroborated
by the appearance of many features of NE cells, like neurite
outgrowth (cell body prolongation longer than twice the cell body
diameter), and the expression of the highly speciﬁc markers for NE
cells class III β tubulin (βIII-Tub). The expression of βIII-Tub as well
as the dominant enolase-isoenzyme found in NE tissues, the
NSE,22 were also determined by western blot (Figure 1b).
In order to study the effect of cannabinoids on prostate LNCaP
cells’ NE differentiation, we choose the non-selective CB1 and CB2
agonist WIN 55,212-2 (WIN). WIN is a synthetic cannabinoid that has
been shown to act on both CB1 and CB2 and one of the most widely
used analogs of endocannabinoids designed to activate cannabi-
noid receptors. In the LNCaP prostate cancer cell line, as well as in
the NE differentiated cells, WIN dose-dependently decreased cell
viability, with an overall IC50 value of 3 μM (Figure 1c). We then used
this dose to investigate whether the cannabinoid WIN had any effect
on the neuroendocrine differentiation (NED) of LNCaP cells. As
shown in Figure 1d, incubation of LNCaP cells with WIN notably and
signiﬁcantly reduced the NE markers NSE and βIII Tub expressed by
NE cells. In order to investigate the involvement of the cannabinoid
receptors, we used the CB1 inverse agonist SR1 and the CB2 inverse
agonist SR2. These compounds when added together did not
modify the effect of WIN.
To reinforce the notion that the cannabinoid WIN abrogated NE
differentiation of prostate LNCaP cells, we used another model of
NE differentiation. As stated previously, NE differentiation of
LNCaP cells can also be induced by long-treatment with IL-6.23 We
then incubated LNCaP cells with 20 ng ml1 of human recombinant
IL-6 for 6 days in the presence or not of 3 mM WIN. IL-6-treated
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blot. GADPH was probed as a loading control. The image is representative of other three experiments. Densitiometric analyses of the western
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cells displayed morphological characteristics of NE cells (not
shown) and increased the expression of NSE and βIII Tub,
conﬁrming the acquisition of a NE phenotype (Figure 2a). When
NE cells were treated with 3 nM WIN a downregulation of NSE and
βIII Tub expression was observed (Figure 2a).
NE differentiation of LNCaP cells induced by serum deprivation
or IL-6 treatment was reversible, and the cells turned back to
control LNCaP when serum was replenished or IL-6 was removed
(not shown). Therefore, to validate the inhibitory effect of WIN
in vivo, we moved to PC-3 cells as they may be considered as a cell
line characteristic of prostatic small cell NE carcinoma.24 In fact,
PC-3 cells express high levels of NE markers such as NSE,
Chromogranin A and βIII Tub, and they do not express AR and
PSA. Moreover, PC-3 cells, usually maintain NE characteristics
along an in vivo experiment even in the presence of the animal
serum. We ﬁrst tested the effect of WIN on PC-3 cells in vitro. Cells
were treated with 3 nM WIN for 6 days and levels of NSE and βIII
Tub were determined. As shown in Figure 2b, the expression of
both markers diminished after 6 days of WIN treatment. Next, PC-3
tumors were generated in male athymic nude mice and treated
with 0.5 mg kg1 WIN for 15 days. WIN-treated PC-3 xenografts grew
slower and the size of the tumors at the end of the experiment was
smaller compared with vehicle-treated PC3 xenografts (Figure 2b).
Likewise, levels of βIII Tub decreased in WIN-treated tumors
compared with non-treated tumors (Figure 2b).
The cannabinoid WIN inhibits the PI3K/AKT/mTOR signaling
pathway in NE differentiated LNCaP cells
To investigate the role of the PI3K/Akt/mTOR pathway in the NE
differentiation of the prostate cancer cell line LNCaP, cells were
deprived of serum for 6 days and phosphorylation levels of Akt
and its downstream signaling proteins mTOR and S6 were deter-
mined by western blotting. Consistent with previous observa-
tions,25,26 the PI3K/Akt signaling pathway was hyper-activated as
deduced by the signiﬁcantly increased levels of phosphorylated
Akt in Ser473, compared with control LNCaP cells (Figure 3a).
Levels of phosphorylated downstream signaling proteins, mTOR
and S6, although not signiﬁcantly, were also increased.
In order to gain insight into the mechanism whereby the
cannabinoid WIN prevented NE differentiation of prostate LNCaP
cells, we analyzed the PI3K/Akt/mTOR pathway. Addition of 3 μM
WIN during serum deprivation, markedly reduced the increase in
phosphorylated Akt, phosphorylated mTOR and phosphorylated
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S6 produced in NE cells, implying a WIN-induced blocking of the
PI3K/Akt pathway (Figure 3b). It is worthy to note that in these
conditions, WIN did not have any effect on PI3K/Akt/mTOR axe in
control cells (Figure 3b).
We then compared the effect of WIN with that produced by the
widely used PI3K/Akt/mTOR signaling cascade inhibitors.
Treatment of cells either with the PI3K inhibitor LY 294002, the
Akt selective inhibitor Inhibitor IV (Inh IV) or the mTOR inhibitor
rapamycin, resulted in a decrease of the NE markers NSE and βIII
Tubulin expression in serum-deprived cells (Figure 4). These
results were comparable to those produced by WIN (Figure 3b).
Interestingly, whereas LY and Akt Inh IV almost totally blocked NSE
and βIII Tubulin expression, the mTOR inhibitor rapamycin, had a
lesser effect. This result indicates that Akt may regulate the
differentiation process by other mTOR-independent mechanisms.
The cannabinoid WIN inhibits NE differentiation by activation
of AMPK
In addition to its energy sensor function, the AMP-activated
protein kinase (AMPK) signaling system has recently emerged as a
modulator of cell proliferation and survival.27 Therefore, AMPK has
been revealed as a novel target for anticancer therapy.28 We then
investigated the effect of WIN treatment on AMPK and the role of
this kinase in NE differentiation. To investigate the role of AMPK in
the NE differentiation of prostate LNCaP cells, cells were serum-
deprived for 6 days and phosphorylation levels of AMPK in Thr172
and its well-established substrate acetyl coenzyme A carboxylase
(ACC) were monitored by western blot. Figure 4a shows that
during NE differentiation there is a decrease in Thr172 phosphor-
ylation of AMPK and in ser 79 of ACC, which indicates an inhibition
of the AMPK pathway. Interestingly, levels of total ACC decrease
during NED, suggesting that AMPK is also regulating ACC
expression. Levels of the NE markers NSE and βIII Tub are shown
as a NE differentiation control (Figure 5a).
When 3 μM WIN was added to the serum-deprived medium, the
inhibition of AMPK observed in NE cells was prevented. This effect
was independent of cannabinoid receptors, as SR1 and SR2 when
combined together did not modify the effect of WIN (Figure 5b).
To further analyze the function of AMPK on NE differentiation,
LNCaP cells were treated with the AMPK pharmacological
activator AICAR during the 6 days of serum deprivation. As shown
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image is representative of other four experiments. Densitiometric analysis of the western blot bands are shown on the right. The data shown
are the means± s.d. of three different experiments. (*Po0.05 and **Po0.01 versus control cells, #Po0.05 and ##Po0.01 versus NE cells,
compared by the Student’s t-test). ACC, acetyl CoA carboxylase; AMPK, AMP-activated protein kinase; NE, neuroendocrine.
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in Supplementary Figure 2, AICAR increased phosphorylation of
ACC in both control and NE cells, indicating that AMPK is active.
Moreover, AICAR treatment rescued the decrease of ACC
expression observed in NE, conﬁrming that AMPK regulates its
expression. Interestingly, as observed with the treatment with
WIN, AMPK activation with AICAR notably reduced the expression
of NED markers NSE and βIII Tub (Supplementary Figure 2).
The effect of Win on the PI3K/Akt pathway and AMPK in NE cells
was further corroborated in IL-6 long-term-treated LNCaP cells.
As shown in Figure 6, in IL-6-induced NE differentiation, a decrease
in p-AMPK and p-ACC is observed, which is in consonance with
serum withdrawal-induced NE differentiation, suggesting that
AMPK inhibition is a general phenomenon of NE differentiation. As
was the case in NE differentiation induced by serum depletion,
treatment with 3 nM WIN increased both p-AMPK and p-ACC in
NE cells.
Suppression of PI3K/Akt/mTOR pathway prevents AMPK inhibition
and reduces NE differentiation
In order to establish a relationship between the two pathways
studied, we determined the effect of PI3K/Akt/mTOR pathway
inhibition on AMPK phosphorylation and activity. When cells were
incubated either with the PI3K inhibitor LY 294002 or with the Akt
inhibitor IV, the decrease of phosphorylated AMPK observed in NE
cells was abrogated (Figure 7). This indicates that inhibition of PI3K
or Akt prevents inhibition of AMPK and, therefore, the PI3K/Akt
pathway modulates AMPK in NE cells. According to this idea, the
NE differentiation-induced diminution in phosphorylated ACC was
prevented in LY 294002 and inhibitor IV-treated cells (Figure 7). In
these conditions, the NE markers NSE and βIII Tubulin also
decreased (Figure 7).
The cannabinoid receptors CB1 and CB2 expression decrease
during NE differentiation of prostate LNCaP cells
We then sought to study whether WIN-induced inhibition of
LNCaP differentiation was linked to CB1 or CB2. The cannabinoid
receptors CB1 and CB2 are constitutive components of the
endocannabinoid system and mediate many of the effects
induced by cannabinoids. Although the effect of the cannabinoid
receptor ligand WIN on signaling cascades of NE cells was not
prevented by the cannabinoid receptors, inverse agonists SR1
and SR2, we decided to analyze the expression levels of both
receptors. Quantitative PCR analyses showed that in NE cells there
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Figure 6. Effect of WIN 55,212-2 on IL-6-induced NE differentiation.
NE differentiation of LNCaP cells was induced by incubation with
IL-6 (20 ng ml1) -supplemented medium for 6 days. Cells were
treated with vehicle (Vhc), 3 μM of WIN (WIN) or 1 μM of the
CB1inverse agonist SR1 and 1 μM of the CB2 inverse agonist SR2
(SR1/SR2) for 6 days. Levels of the phosphorylated and total forms of
Akt, AMPK and acetyl CoA carboxylase (ACC) proteins were
determined by western blot. GADPH was probed as a loading
control. The image is representative of other three experiments. IL,
interleukin; NE, neuroendocrine.
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Figure 7. Suppression of PI3K/Akt activation prevents AMPK inhibition. LNCaP control and NE cells were treated with the PI3K inhibitor LY
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was a dramatic decrease in CB1 and CB2 expression (Figure 8a).
Immunoblotting revealed that serum withdrawal reduced the
expression of CB2 protein in a time-dependent manner
(Figure 8b). Then we treated cells with 3 μM WIN during serum
deprivation and found that NE cells treated with WIN not only
preserved but increased CB2 mRNA levels compared with control
cells (Figure 8c). These results indicate that WIN treatment
prevents CB2 decay during NE differentiation, which could
mediate the NE differentiation inhibition induced by WIN.
DISCUSSION
The purpose of this study was to analyze the signaling pathway
involved in NE differentiation of prostate LNCaP cells and the
inﬂuence of WIN 55,212-2 on this process. Compelling evidence
has implicated the endocannabinoid system in the regulation of
cell fate. Natural cannabinoids as well as synthetic cannabinoid
receptor ligands have been shown to reduce tumor cell
proliferation, including prostate tumor cells.9,29 However, little is
known about the role of cannabinoids on the NE differentiation of
tumors. Here, we demonstrate that the cannabinoid WIN prevents
NE differentiation of LNCaP cells by inhibition of PI3K/Akt/mTOR
activation and stimulation of AMPK, providing a promising
therapeutic opportunity for NE differentiated prostate cancer
(Figure 9).
The PI3K/Akt/mTOR axe controls many functions in prostate
cells including cell survival, growth and proliferation. Moreover,
preclinical studies reveal a dynamic interplay between PI3K and
androgen receptor during the development of androgen-
deprivation therapy resistance.30 Therefore, it seems like the
suppression of androgen signaling is one of the stimulus that
induces activation of PI3K/Akt. According to this, it has been
recently demonstrated that androgen receptor negatively reg-
ulates PI3K through repression of the regulatory subunit p85α
protein.31 Our results are in line with this idea as serum
deprivation of LNCaP cells increased AKT phosphorylation at
Ser473 as well as the phosphorylation of its downstream signaling
protein S6, which correlated with the increase in NE markers
expression. Similar results showed by Qi et al.32 indicate that
androgen-depletion increased AR protein level and Akt phosphor-
ylation at Ser473 and Thr308 in LNCaP cells. The importance of the
PI3K/Akt signaling pathway in NE differentiation of LNCaP cells has
been also reported by other groups.25,33 Long-term exposure of
LNCaP cells to the cytokine IL-6 causes irreversible NE differentia-
tion and activation of the PI3K/Akt cascade.26,34 Our results are
in line with this notion as IL-6 treatment of LNCaP cells induced an
increase of NE markers and p-mTOR. Activation of Akt has
also been observed in other models of NE differentiation. For
instance, NE differentiation of LNCaP cells by treatment with the
neuropeptide VIP induces cAMP increase and activation of PKA
and PI3K.33 These results indicate that the activation of the PI3K/
Akt route is a general mechanism associated with NE differentia-
tion of prostate cells at least in vitro. Our results showing an
inhibition of this pathway by the cannabinoid WIN indicate that
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Figure 8. NE differentiation of LNCaP cells induces a decrease of cannabinoid receptors CB1 and CB2 expression. (a) Cannabinoid receptors
CB1 and CB2 mRNAs levels in LNCaP control and NE cells analyzed by quantitative PCR according to the Materials and Methods section.
(b) LNCaP cells were serum-deprived for 2, 4 and 6 days and levels of the cannabinoid receptor CB2 protein and NE markers neuron-speciﬁc
enolase (NSE) and βIII tubulin (βIII Tub) were analyzed by western blot. GADPH was probed as a loading control. The image is representative of
other three experiments. Densitiometric analysis of the western blot bands of CB2 is shown on the left. (c) LNCaP control and NE cells were
treated with vehicle (Vhc), 3 μM of WIN 55-212,2 (WIN) 1 μM of the cannabinoid receptor inverse agonists SR1 and SR2 (SR1/SR2) or combined
together for 6 days. Levels of CB1 and CB2 mRNA were analyzed by quantitative PCR according to the Materials and Methods section. The
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WIN is probably acting at the beginning of the process and that
this cannabinoid may be useful for the treatment of NE cancers.
We believe our ﬁndings also demonstrate for the ﬁrst time that
AMPK is inhibited in NE cells. Similar to our ﬁndings demonstrat-
ing an inhibitory effect of AICAR on NED, activation of AMPK with
metformin reduced the aggressiveness of NE tumors of the
gastro–entero–pancreatic system.35 Recent clinical studies on
patients with well-differentiated pancreatic NE tumors, showed
that the survival of metformin-treated patients was twice that
observed in the control group.36 To our knowledge, our work is
the ﬁrst study regarding the role of AMPK on NE differentiation of
prostate cells. We also found that Akt activation is involved in the
AMPK inactivation, and such AMPK inhibition contributes to NE
differentiation of prostate LNCaP cells. Recent ﬁndings shown by
other authors demonstrated that AKT activation induced AMPK
Ser485 phosphorylation, which negatively regulated AMPK activity
by inhibiting the Thr172 phosphorylation.37 In line with this,
results by Lin et al.38 recently demonstrated that AKT activation in
basophils could rapidly inhibit AMPK activation through increased
AMPK phosphorylation at the inhibitory Ser485/491 residues, and
this was accompanied by a reduction of ACC phosphorylation. In
addition, data shown by Kim et al.39 revealed that cortical neurons
chronically treated with insulin underwent Akt activation, which
provoked an increase of AMPK phosphorylation in Ser485 and
inhibition of AMPK activity. Although we have not determined the
AMPK phosphorylation in Ser485, our results show that inhibition
of PI3K as well as Akt, abrogated the inhibition of AMPK in NE cells,
providing a signaling link between Akt and AMPK in NED of
prostate cells. Therefore, inhibition of PI3K/Akt by the cannabinoid
WIN would remove the inhibitory phosphorylation of AMPK
resulting in AMPK activation and prevention of NE differentiation
(Figure 9).
A major ﬁnding of our study is the spectacular decrease in
cannabinoid receptors during the NE-differentiation process. The
cannabinoid receptors would exert a tonic inhibition of NE
differentiation in prostate cells even in the absence of ligand and,
therefore, a decrease of cannabinoid receptors may be concomi-
tant to NE differentiation.
In line with our results, data shown by Sugawara et al.,40
demonstrated that CB1 knockdown increased the differentiation
of mast cells from resident progenitor cells and treatment with the
endogenous cannabinoid ligand anandamide counteracted the
activation of mast cells. The role of cannabinoid receptors in NE
differentiation is not surprising as those receptors change their
expression pattern along neuronal differentiation,41 and NE
differentiation of prostate tumors resembles features of neurons.
Further research with endocannabinoids and its receptors will
throw additional light on the actions of these compounds on
prostate tumors differentiation and growth.
In perspective, cannabinoids could represent a viable strategy
to prevent or delay the progression of advanced prostate cancer
with NE differentiation features.
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